BSE:524396

Stock Analysis Report

Biofil Chemicals and Pharmaceuticals

Executive Summary

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical, chemical, and plastic businesses primarily in India.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.

Share Price & News

How has Biofil Chemicals and Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.2%

524396

3.0%

IN Pharmaceuticals

3.1%

IN Market


1 Year Return

-40.3%

524396

-18.9%

IN Pharmaceuticals

3.7%

IN Market

Return vs Industry: 524396 underperformed the Indian Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 524396 underperformed the Indian Market which returned 3.7% over the past year.


Shareholder returns

524396IndustryMarket
7 Day-3.2%3.0%3.1%
30 Day-23.6%-4.2%5.7%
90 Day-37.6%-2.5%1.4%
1 Year-40.3%-40.3%-18.2%-18.9%5.9%3.7%
3 Year-36.8%-36.8%-26.1%-27.6%22.3%16.0%
5 Year108.1%108.1%-11.7%-14.3%42.5%28.9%

Price Volatility Vs. Market

How volatile is Biofil Chemicals and Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biofil Chemicals and Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

13.92x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: 524396 (₹4.6) is trading above our estimate of fair value (₹1.81)

Significantly Undervalued: 524396 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524396 is good value based on its PE Ratio (13.9x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 524396 is poor value based on its PE Ratio (13.9x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 524396's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524396 is good value based on its PB Ratio (0.7x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Biofil Chemicals and Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524396's forecast earnings growth (24.7% per year) is above the savings rate (7.6%).

Earnings vs Market: 524396's earnings (24.7% per year) are forecast to grow faster than the Indian market (18.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 524396's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 524396's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 524396's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biofil Chemicals and Pharmaceuticals performed over the past 5 years?

3.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 524396's earnings have grown by 3.2% per year over the past 5 years.

Accelerating Growth: 524396's earnings growth over the past year (20.1%) exceeds its 5-year average (3.2% per year).

Earnings vs Industry: 524396 earnings growth over the past year (20.1%) exceeded the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: 524396's Return on Equity (3.8%) is considered low.


Return on Assets

ROA vs Industry: 524396's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 524396's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Biofil Chemicals and Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 524396's short term assets (₹139.2M) exceeds its short term liabilities (₹105.6M)

Long Term Liabilities: 524396's short term assets (139.2M) exceeds its long term liabilities (100.0)


Debt to Equity History and Analysis

Debt Level: 524396's debt to equity ratio (12%) is considered satisfactory

Reducing Debt: 524396's debt to equity ratio has reduced from 36.6% to 12% over the past 5 years.

Debt Coverage: 524396's debt is well covered by operating cash flow (76.7%).

Interest Coverage: 524396's interest payments on its debt are well covered by EBIT (5.1x coverage).


Balance Sheet

Inventory Level: 524396 has a high level of physical assets or inventory.

Debt Coverage by Assets: 524396's debt is covered by short term assets (assets are 8.501020x debt).


Next Steps

Dividend

What is Biofil Chemicals and Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 524396's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 524396's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 524396's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524396's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524396's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Biofil Chemicals and Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

14.3yrs

Average board tenure


CEO

Ramesh Shah (83yo)

0yrs

Tenure

0

Mr. Ramesh S. Shah serves as the Managing Director of Biofil Chemicals & Pharmaceuticals Ltd. and served as its Compliance Officer. Mr. Shah serves as the Chairman of Biofil Chemicals & Pharmaceuticals Ltd ...


Board Age and Tenure

14.3yrs

Average Tenure

62yo

Average Age

Experienced Board: 524396's board of directors are seasoned and experienced ( 14.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ramesh Shah (83yo)

    Chairman

    • Tenure: 0yrs
  • Ketan Shah (58yo)

    Chief Operating Officer

    • Tenure: 0yrs
  • Jitendra Sahu (33yo)

    Chief Finance Officer

    • Tenure: 5.4yrs
    • Compensation: ₹318.00k
  • Shikha Khilwani (30yo)

    Company Secretary & Compliance Officer

    • Tenure: 3.7yrs
    • Compensation: ₹304.50k
  • Akshay Atri (28yo)

    Marketing Manager

    • Tenure: 0yrs
  • Joseph Chacko (58yo)

    Head of Administration

    • Tenure: 0yrs
  • Vinayak Bhopte (45yo)

    Chief Chemist

    • Tenure: 0yrs

Board Members

  • Ramesh Shah (83yo)

    Chairman

    • Tenure: 0yrs
  • Romil Shah (34yo)

    Non-Executive Director

    • Tenure: 14.3yrs
  • Shaila Jain (53yo)

    Non Executive Independent Director

    • Tenure: 16.8yrs
  • Subhash Swarnkar (71yo)

    Non-Executive Independent Director

    • Tenure: 4.2yrs

Company Information

Biofil Chemicals and Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biofil Chemicals and Pharmaceuticals Limited
  • Ticker: 524396
  • Exchange: BSE
  • Founded: 1985
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹76.812m
  • Shares outstanding: 16.27m
  • Website: https://www.biofilgroup.net

Number of Employees


Location

  • Biofil Chemicals and Pharmaceuticals Limited
  • B-12/B, Industrial Estate
  • Pologround
  • Indore
  • Madhya Pradesh
  • 452015
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524396BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2001
BIOFILCHEMNSEI (National Stock Exchange of India)YesEquity SharesININRDec 2001

Biography

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical, chemical, and plastic businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potas ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 12:37
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.